$417 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | New | ALNYLAM PHARMACEUTICALS INCput | $21,878,000 | – | 150,000 | +100.0% | 5.25% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $18,850,000 | – | 149,000 | +100.0% | 4.52% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $14,535,000 | – | 193,900 | +100.0% | 3.49% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $11,970,000 | – | 3,150,000 | +100.0% | 2.87% | – |
| ALKS | New | ALKERMES PLC | $10,773,000 | – | 361,636 | +100.0% | 2.58% | – |
| DTIL | New | PRECISION BIOSCIENCES INC | $9,209,000 | – | 5,755,396 | +100.0% | 2.21% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $7,311,000 | – | 75,000 | +100.0% | 1.75% | – |
| KRTX | New | KARUNA THERAPEUTICS INCput | $6,945,000 | – | 54,900 | +100.0% | 1.67% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $4,585,000 | – | 538,819 | +100.0% | 1.10% | – |
| ETNB | New | 89BIO INC | $4,508,000 | – | 1,400,000 | +100.0% | 1.08% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $2,862,000 | – | 357,263 | +100.0% | 0.69% | – |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $2,268,000 | – | 432,000 | +100.0% | 0.54% | – | |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $1,263,000 | – | 2,500,000 | +100.0% | 0.30% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.